CN1934128A - 在2价阳离子存在下通过加热处理制备人血清白蛋白的方法 - Google Patents
在2价阳离子存在下通过加热处理制备人血清白蛋白的方法 Download PDFInfo
- Publication number
- CN1934128A CN1934128A CNA2005800090238A CN200580009023A CN1934128A CN 1934128 A CN1934128 A CN 1934128A CN A2005800090238 A CNA2005800090238 A CN A2005800090238A CN 200580009023 A CN200580009023 A CN 200580009023A CN 1934128 A CN1934128 A CN 1934128A
- Authority
- CN
- China
- Prior art keywords
- serum albumin
- human serum
- heat treated
- ion
- impurity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 92
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 83
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 81
- 238000010438 heat treatment Methods 0.000 title abstract description 16
- 150000001768 cations Chemical class 0.000 title abstract description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 25
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- -1 iron ion Chemical class 0.000 claims abstract description 7
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910001429 cobalt ion Inorganic materials 0.000 claims abstract description 6
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052742 iron Inorganic materials 0.000 claims abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 6
- 229910001453 nickel ion Inorganic materials 0.000 claims abstract description 6
- 239000012535 impurity Substances 0.000 claims description 51
- 238000002360 preparation method Methods 0.000 claims description 32
- 238000000746 purification Methods 0.000 claims description 32
- 150000002500 ions Chemical class 0.000 claims description 22
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 14
- 238000010353 genetic engineering Methods 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000005192 partition Methods 0.000 claims description 5
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 230000002546 agglutinic effect Effects 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 41
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- 239000007788 liquid Substances 0.000 description 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 238000005341 cation exchange Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 2
- 208000003623 Hypoalbuminemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000012366 Fed-batch cultivation Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
钙离子浓度(mM) | 加热后杂质的含量(μg/grHA) | 除去率(%) |
0 | 788 | 34.1 |
5 | 683 | 42.9 |
50 | 475 | 60.3 |
100 | 205 | 82.9 |
钙离子浓度(mM) | 加热后杂质的含量(μg/grHA) | 除去率(%) |
0 | 322 | 73.1 |
5 | 230 | 80.8 |
50 | 111 | 90.7 |
100 | 91 | 92.4 |
加热处理(Ca+辛酸Na)(时间) | 加热后杂质的含量(μg/grHA) | 除去率(%) |
1 | 56.6 | 99.92 |
2 | 43.3 | 99.94 |
3 | 35.0 | 99.95 |
5 | 29.2 | 99.96 |
10 | 27.5 | 99.96 |
24 | 19.0 | 99.97 |
加热温度 | 加热温度(分钟) | 加热后杂质含量(μg/grHA) | 除去率(%) | ||
Ca- | Ca+ | Ca- | Ca+ | ||
50℃ | 1 | 44036 | 41464 | 26.78 | 31.06 |
50℃ | 30 | 36493 | 17596 | 39.33 | 70.74 |
50℃ | 60 | 21101 | 5997 | 64.92 | 90.03 |
60℃ | 1 | 2253 | 1168 | 96.25 | 98.06 |
60℃ | 30 | 1138 | 182 | 98.11 | 99.70 |
60℃ | 60 | 972 | 323 | 98.38 | 99.46 |
70℃ | 1 | 940 | 194 | 98.44 | 99.68 |
70℃ | 30 | 201 | 21 | 99.67 | 99.97 |
80℃ | 1 | 1007 | 229 | 98.33 | 99.62 |
离子的种类 | 加热后杂质的含量(μg/grHA) | 除去率(%) |
未添加 | 1156 | 98.28 |
钙离子 | 420 | 99.37 |
镁离子 | 828 | 98.77 |
钴离子 | 345 | 99.49 |
镍离子 | 572 | 99.15 |
铁离子 | 555 | 99.17 |
锌离子 | 920 | 98.63 |
钙离子浓度(mM) | 加热后杂质的含量(μg/grHA) | 除去率(%) |
100 | 0.069 | 99.48 |
250 | 0.032 | 99.76 |
500 | 检测限以下 | 99.83以上 |
750 | 检测限以下 | 99.73以上 |
1000 | 检测限以下 | 99.03以上 |
加热处理(时间) | 加热后杂质的含量(μg/grHA) | 除去率(%) |
1 | 0.085 | 99.60 |
16 | 检测限以下 | 99.88以上 |
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP012054/2004 | 2004-01-20 | ||
JP2004012054 | 2004-01-20 | ||
PCT/JP2005/000647 WO2005068489A1 (ja) | 2004-01-20 | 2005-01-20 | 2価陽イオン存在下加熱処理によるヒト血清アルブミンの製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1934128A true CN1934128A (zh) | 2007-03-21 |
CN1934128B CN1934128B (zh) | 2011-01-26 |
Family
ID=34792362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800090238A Active CN1934128B (zh) | 2004-01-20 | 2005-01-20 | 在2价阳离子存在下通过加热处理制备人血清白蛋白的方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7531631B2 (zh) |
EP (1) | EP1710250B1 (zh) |
JP (1) | JP4644604B2 (zh) |
KR (1) | KR20070020204A (zh) |
CN (1) | CN1934128B (zh) |
AT (1) | ATE428722T1 (zh) |
AU (1) | AU2005205314B2 (zh) |
CA (1) | CA2559379A1 (zh) |
DE (1) | DE602005013912D1 (zh) |
DK (1) | DK1710250T3 (zh) |
WO (1) | WO2005068489A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749623A (zh) * | 2016-12-09 | 2017-05-31 | 浙江大学 | 一种基于混合模式的扩张床吸附分离人血白蛋白方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE486936T1 (de) * | 2003-03-05 | 2010-11-15 | Chemo Sero Therapeut Res Inst | Verfahren zur herstellung eines heterologen proteins in e. coli |
BRPI0616242A2 (pt) * | 2005-09-15 | 2011-06-14 | Wyeth Corp | floculaÇço de proteÍna usando sais |
JP4936272B2 (ja) * | 2006-02-13 | 2012-05-23 | 独立行政法人科学技術振興機構 | バイオナノカプセルの効率的な精製法 |
WO2010096588A2 (en) | 2009-02-20 | 2010-08-26 | Ventria Bioscience | Cell culture media containing combinations of proteins |
KR101933952B1 (ko) | 2011-07-01 | 2018-12-31 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 발광 장치, 전자 기기 및 조명 장치 |
WO2014098464A1 (ko) * | 2012-12-18 | 2014-06-26 | 이화여자대학교 산학협력단 | 인간혈청알부민 열안정화용 조성물 및 이를 이용한 열안정화된 인간혈청알부민의 제조방법 |
JP6182465B2 (ja) * | 2014-01-29 | 2017-08-16 | シスメックス株式会社 | ペプチドの回収方法 |
CA3038422A1 (en) | 2016-10-04 | 2018-04-12 | Albumedix Ltd | Uses of recombinant yeast-derived serum albumin |
EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
JPH0671434B2 (ja) | 1989-09-18 | 1994-09-14 | 株式会社ミドリ十字 | ヒト血清アルブミンの製造方法 |
US5440018A (en) | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
JPH07102148B2 (ja) * | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
JP2869417B2 (ja) | 1992-09-22 | 1999-03-10 | 吉富製薬株式会社 | 遺伝子操作により得られるヒト血清アルブミン |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
JPH07126182A (ja) | 1993-10-27 | 1995-05-16 | Green Cross Corp:The | 組換えヒト血清アルブミン製剤の滅菌方法 |
JP2885212B2 (ja) * | 1997-01-06 | 1999-04-19 | 吉富製薬株式会社 | 遺伝子操作由来のヒト血清アルブミンより得られる高純度ヒト血清アルブミン含有組成物 |
EP0886322A3 (en) | 1997-06-16 | 1999-02-03 | Eastman Kodak Company | Packaging of imaging devices |
KR100252052B1 (ko) | 1997-12-03 | 2000-04-15 | 윤종용 | 셀 테스트 패턴을 사용하여 강유전체 기억소자의 특성을 평가하는 방법 |
JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
JP4060639B2 (ja) | 2002-05-15 | 2008-03-12 | 日本電信電話株式会社 | データ管理装置 |
JP5292993B2 (ja) | 2008-08-20 | 2013-09-18 | 株式会社Ihi | 鋼床版 |
-
2005
- 2005-01-20 CN CN2005800090238A patent/CN1934128B/zh active Active
- 2005-01-20 AT AT05703875T patent/ATE428722T1/de not_active IP Right Cessation
- 2005-01-20 AU AU2005205314A patent/AU2005205314B2/en not_active Ceased
- 2005-01-20 WO PCT/JP2005/000647 patent/WO2005068489A1/ja active Application Filing
- 2005-01-20 KR KR1020067016346A patent/KR20070020204A/ko not_active Application Discontinuation
- 2005-01-20 CA CA002559379A patent/CA2559379A1/en not_active Abandoned
- 2005-01-20 DE DE602005013912T patent/DE602005013912D1/de active Active
- 2005-01-20 EP EP05703875A patent/EP1710250B1/en active Active
- 2005-01-20 DK DK05703875T patent/DK1710250T3/da active
- 2005-01-20 JP JP2005517123A patent/JP4644604B2/ja active Active
-
2006
- 2006-07-20 US US11/489,541 patent/US7531631B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749623A (zh) * | 2016-12-09 | 2017-05-31 | 浙江大学 | 一种基于混合模式的扩张床吸附分离人血白蛋白方法 |
CN106749623B (zh) * | 2016-12-09 | 2020-04-10 | 浙江大学 | 一种基于混合模式的扩张床吸附分离人血白蛋白方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1710250A1 (en) | 2006-10-11 |
KR20070020204A (ko) | 2007-02-20 |
DE602005013912D1 (de) | 2009-05-28 |
AU2005205314A1 (en) | 2005-07-28 |
US7531631B2 (en) | 2009-05-12 |
JPWO2005068489A1 (ja) | 2007-12-27 |
DK1710250T3 (da) | 2009-07-06 |
EP1710250B1 (en) | 2009-04-15 |
JP4644604B2 (ja) | 2011-03-02 |
ATE428722T1 (de) | 2009-05-15 |
AU2005205314B2 (en) | 2010-12-09 |
US20060258850A1 (en) | 2006-11-16 |
WO2005068489A1 (ja) | 2005-07-28 |
CA2559379A1 (en) | 2005-07-28 |
EP1710250A4 (en) | 2007-07-11 |
CN1934128B (zh) | 2011-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1934128A (zh) | 在2价阳离子存在下通过加热处理制备人血清白蛋白的方法 | |
CN105358694B (zh) | 来自巴斯德毕赤酵母的酵母启动子 | |
CN1515591A (zh) | 生长激素和血清白蛋白重组融合蛋白 | |
ES2716619T3 (es) | Promotores de levadura para la expresión de proteínas | |
CN1313493C (zh) | 包括加热处理步骤的人血清白蛋白的制造方法 | |
CN1295580A (zh) | 制造鼠和人内源性血管生成抑制因子的方法 | |
TW200804412A (en) | Purified vegetarian protein a and process for production thereof | |
JP2019048807A (ja) | たんぱく質精製の新規な方法 | |
CN108822202B (zh) | 一种草鱼白细胞介素21重组蛋白及其制备方法 | |
JP5908496B2 (ja) | トランスジェニックイネの子実からヒト血清アルブミンを抽出する方法 | |
TW390889B (en) | Process for purifying recombinant human serum albumin | |
CN1075148A (zh) | 新的巨核细胞扩增基因 | |
CN107778365B (zh) | 一种多点整合的重组蛋白表达方法 | |
CN1680443A (zh) | 含有白蛋白多聚体的重组蛋白 | |
CN1782067A (zh) | 采用gs115酵母菌合成重组人肠三叶因子的工艺 | |
WO2002034785A1 (fr) | Procede de monomerisation de polymeres d"albumine serique humaine | |
RU2733423C1 (ru) | Штамм метилотрофных дрожжей Pichia pastoris Yst-HSA-PDI1, продуцирующий рекомбинантный человеческий сывороточный альбумин | |
CN1924001A (zh) | 用甲基营养酵母生产人热休克蛋白70的方法 | |
CN104694522A (zh) | 一种重组乙酰化阳离子型胰蛋白酶的制备方法及其应用 | |
CN85107120A (zh) | 重组体dna及其用途 | |
JP2015518723A (ja) | トリコデルマ(Trichoderma)ヒドロホビン産生 | |
WO2004048588A1 (en) | Process for purifying a fermentation-derived product | |
CN111434693B (zh) | 一种抗氧化融合蛋白及应用 | |
CN114561395B (zh) | 无融合标签的rhIL-11及其突变体的可溶表达及高效纯化方法 | |
CN1831126A (zh) | 重组胸腺素α1在大肠杆菌中的高分泌表达和分离纯化 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Xiongben County, Xiongben, Japan Patentee after: THE CHEMO-SERO-THERAPEUTIC Research Institute Address before: Xiongben County Patentee before: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC Research Institute |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190530 Address after: Kumamoto, Japan Patentee after: THE CHEMO-SERO-THERAPEUTIC Research Institute Address before: Xiongben County, Xiongben, Japan Patentee before: THE CHEMO-SERO-THERAPEUTIC Research Institute |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200917 Address after: England Patentee after: ALBUMEDIX A/S Address before: Kumamoto, Japan Patentee before: THE CHEMO-SERO-THERAPEUTIC Research Institute |
|
TR01 | Transfer of patent right |